2020201920182017201620152014 June 01, 2020 Summary ToggleSpero Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference June 01, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 08, 2020 Summary ToggleSpero Therapeutics Announces First Quarter 2020 Operating Results and Provides Business Update May 05, 2020 Summary ToggleSpero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection May 04, 2020 Summary ToggleSpero Therapeutics to Provide Business Update and Report First Quarter 2020 Financial Results on Friday, May 8, 2020 April 30, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 16, 2020 Summary ToggleSpero Announces Appointment of Scott Jackson to its Board of Directors March 31, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 16, 2020 Summary ToggleSpero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update March 11, 2020 Summary ToggleSpero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
